Showing results (81-90 of 160) with videos related to
Sort By:
Pageof 16
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 10, 2011
Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trialLian Engelen, Frederik Persson, Isabel Ferreira, et al.Journal of Diabetes and Its Complications|May 3, 2017
Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trialsBernt Johan von Scholten, Melanie J Davies, Frederik Persson, et al.Diabetes Care|July 27, 2011
initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trialMerel E Hellemons, Frederik Persson, Stephan J L Bakker, et al.Clinical Journal of the American Society of Nephrology : CJASN|January 9, 2015
Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathyTobias F Kröpelin, Dick de Zeeuw, Dennis L Andress, et al.Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|October 31, 2012
Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney diseaseStine E Nielsen, Katrine J Schjoedt, Kasper Rossing, et al.Diabetologia|July 7, 2017
Toe-brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuriaEmilie H Zobel, Bernt Johan von Scholten, Henrik Reinhard, et al.Frontiers in Pharmacology|May 16, 2022
Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator ReceptorViktor Rotbain Curovic, Morten B Houlind, Tine W Hansen, et al.Diabetes Care|March 20, 2019
Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 DiabetesViktor Rotbain Curovic, Simone Theilade, Signe A Winther, et al.Immunobiology|March 22, 2024
Effect of dapagliflozin on collectins and complement activation in plasma from patients with type 2 diabetes and albuminuria: Data from the DapKid cohortMia Jensen, Mie K Eickhoff, Frederik Persson, et al.Journal of Sports Sciences|December 6, 2023
The effect of metformin treatment on volumes of free-living physical activity and sedentary behaviour: A post-hoc analysis of the PRE-D trialKristian Karstoft, Mathias Ried-Larsen, Lea Bruhn, et al.Pageof 16